Blood matching test to be offered to patients with rare conditions
The new test uses genetics to generate detailed blood group information.
It is the first time it has been used for patients with rare inherited anaemias – with around 300 people eligible for testing, according to NHS Blood and Transplant (NHSBT).
The programme has been backed by the family of toddler Woody Mayers, aged 22 months, who has a rare inherited anaemia called congenital dyserythropoietic anaemia (CDA) type 1.
The condition causes the bone marrow to struggle to produce healthy red blood cells, which carry oxygen around the body.
Woody Mayers, now 22 months, was born with an extremely rare blood disorder (NHSBT/Family handout)
It is estimated to affect between one to five out of every million babies.
Patients have low haemoglobin levels, meaning Woody relies on blood transfusions every four weeks to stay alive.
However, the donor blood must be carefully matched to reduce the risk of patient's developing antibodies against certain blood types, which can cause severe reactions and make transfusions more difficult in the future.
The new genotyping testing programme, a partnership between NHSBT and NHS England, uses genetics to identify more of the rarer blood groups.
Samples are collected at routine hospital appointments, with patients' DNA tested to find out their blood types.
About 300 people with transfusion dependent, rare inherited anaemias, are eligible for the test.
All patients with sickle cell disorder and thalassaemia are also eligible, even if they do not rely on blood transfusions.
Kate Downes, head of genomics at NHSBT, said: 'The new genotyping test can test blood groups faster and more extensively than standard testing methods.'
Professor Dame Sue Hill, chief scientific officer at NHS England, said: 'The power of genomics is transforming medicine, with extended blood group genotyping now being utilised to help patients, especially those requiring regular transfusions.
'This is an exceptional example of an evidence-based innovation, developed from genetic data, being used to drive forward improvements that will make a huge difference across the NHS.
'Blood donations can be lifesaving for patients, and the NHS needs a constant flow of donations to provide people with the best possible care, so I'd encourage anyone who can donate to do so.'
Woody's family were alerted to potential health conditions at a 20-week pregnancy scan.
He was born prematurely at 34 weeks with haemoglobin levels around a quarter of what they should have been.
Woody's mother Polly was alerted to her son's health condition at a pregnancy scan (NHSBT/Family handout)
Woody's mother Polly Mayers, 35, from Robertsbridge in East Sussex, said: 'When he was born, he was very poorly and pale. He didn't cry for a few minutes. He needed ventilation breaths. It was really frightening.
'The first few days were very critical for Woody. He was extremely unwell. Nobody knew the cause for his haemolytic anaemia.'
The toddler has now being having regular transfusions fore more than a year, receiving 140mls of red blood cells every four weeks to boost his haemoglobin.
Despite this, his family describes him as an energetic little boys who likes trips to the park and riding his bike.
His mother added: 'Woody will need the blood to be well-matched so that his transfusions don't become too difficult or risky.
'The test will help him and anyone else with a similar condition. I hope everyone eligible gets it.'
Woody, who is 22 months, enjoys trips to the park and riding his bike (NHSBT/Family handout)
Ms Downes said: 'Woody has very rare disorder and he relies on blood transfusions to stay alive but these need to be well matched.
'We want everyone eligible, like Woody, to be tested so they can get better matched blood. We also need more people to donate, so we can supply the matched lifesaving blood to Woody and people like him.'
Woody's family are also urging people to donate blood.
Mrs Mayers, a community matron, said: 'There's no way to sugar-coat it – if it wasn't for blood donors, Woody would not be alive.
'I'm incredibly grateful to blood donors for ensuring blood is available when he needs it.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
7 minutes ago
- The Sun
New treatment for devastating cancer that DOUBLES survival rate to be rolled out on NHS
THOUSANDS of Brits with bladder cancer could survive for twice as long after a new treatment is given the green light to be dished out on the NHS. Health chiefs have said the approval marks "one of the most hopeful advances in decades for people with bladder cancer". They said there had been real 'unmet need' for patients with the advanced form of the disease. With bladder cancer, up to 29 per cent of people are diagnosed at stage 4, when it has already spread, and only survive for around a year after diagnosis. The treatment is a combination of enfortumab vedotin, an antibody drug made by Astellas and Pfizer, and pembrolizumab, made by Merck. It was approved for use by the National Institute for Health and Care Excellence (Nice) yesterday, which means it can now be used on the NHS for people with bladder cancer. The combination, when tested in clinical trials, gave patients and average of 33.8 months compared with 15.9 months while having chemotherapy. Scientists have also measured the amount of time people that survived without their disease getting worse. They found that those on the treatment had a progression-free survival time of a year compared with six months for those receiving standard treatment. Three in ten patients had no evidence of cancer remaining after the treatment, compared with 14.5 per cent of patients receiving standard care. Martyn Hewett, 75, from Stratford, East London, received the new treatment at Barts Health NHS Trust, after surgery to remove his tumours failed. He said: "I feel very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. The signs and symptoms of cancer "Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said 'most people in your position live for a year', and now, three-and-a-half years later, here I am. "I am going to have an extra few years to see my grandson grow up and maybe even be around to see him get married." The treatment is given via an IV infusion to those whose cancer has spread around their body and cannot be surgically removed. The first drug, enfortumab vedotin, directly targets the cancer cells and kills them, while pembrolizumab helps the immune system to recognise and fight any remaining cancer cells. As well as experiencing better survival rates, patients also have fewer harmful side-effects. About 10,500 people in the UK are diagnosed with bladder cancer each year. The new treatment should help about 1,250 patients annually. Helen Knight, director of medicines evaluation at Nice, said: "This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives." 3 3 Professor Peter Johnson, NHS England's national clinical director for cancer, said: "This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival. "Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks and our rollout to NHS patients will make a huge difference to the lives of those affected and their families." Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: "This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available."
Daily Mail
34 minutes ago
- Daily Mail
Mum found dead in bed at Travelodge 'after being discharged by hospital where doctors irreversibly damaged her brain'
A mother-of-one took her own life after being discharged from specialist mental health services despite still struggling with postpartum psychosis, an inquest has heard. Roisin Harron, from south London, had been suffering from the debilitating illness following the birth of her son in 2017. The 41-year-old, who had a history of depression, started treatment at Bethlem Royal Hospital, Bromley in 2018 following a week of hypermania—periods of abnormally elevated mood and energy levels. As part of her treatment Ms Harron underwent several rounds of electroconvulsive therapy (ECT)—which involves sending an electric current through a patient's brain. Under NHS guidelines, ECT should only be used as a short-term treatment if a patients, with repeated ECT only recommended if a patient has previously responded well to the treatment. But, an inquest in her death, found it was 'impossible to underestimate the impact psychiatric medication had in Roisin's life'. It also heard that Ms Harron felt 'her brain was in some was irreversibly damaged', following the treatment. Her parents, Margaret McMahon and Henry Harron told the South London Coroner's Court in Croydon: 'Roisin had been so unwell and such a risk to herself. But there had been much progress over the years. 'She tried to help herself and seemed to want to do her best at the things that mattered to her—being a good mother, being good at her job and working hard on her relationships with family and friends. 'Prior to he illness, Roisin had an incredibly good memory but during her hospitalisation her memory became quite impaired.' Ms Harron was then diagnosed with bipolar disorder—a mental health condition characterised by extreme mood changes from manic highs to depressive lows. She was prescribed a number of different medications to try and manage her symptoms, including antipsychotics and lithium—a long-term treatment typically prescribed for at least six months. But, the trial and error nature of finding an effective treatment whilst managing Ms Harron's symptoms proved incredibly difficult, causing her stress and anxiety, the inquest heard. In April 2023, Ms Harron was discharged from the specialist mental health services at South London and Maudsley NHS Foundation Trust and put back into the care of her GP at Paxton Green Group Practice, London. But her family told the inquest they were skeptical and did not feel that their daughter was well enough to be discharged and navigate her illness without the support of mental health professionals. They said: 'It was clear that beneath the smiling and friendly face that Roisin presented to the world, there were very difficult struggles going on. What is postpartum psychosis Postpartum psychosis is a serious mental health illness that can cause new mothers to experience hallucinations and delusions. It affects around one-to-two in every 1,000 births, according to Postpartum Support International. PP is different from the 'baby blues', which many mothers experience while they struggle to cope with the stress and hormonal changes that come with having children. It is also different from postnatal depression, which affects one in 10 women to some extent. This can cause feelings of helplessness, as well as a loss of interest in the baby and crying frequently. PP's symptoms usually start within the first two weeks. Some include: Manic mood Depression Loss of inhibitions Feeling paranoid or afraid Restlessness Confusion Acting out of character Its cause is unclear. Women are thought to be more at risk if they have: A family history of mental illness, particularly PP Bipolar disorder or schizophrenia A traumatic birth or pregnancy Suffered from PP in the past Ideally, patients should be put on a specialist psychiatric unit, called a mother and baby unit (MBU), where they can still be with their child. They may be admitted to a general psychiatric ward until a MBU becomes available. Antidepressants may be prescribed to ease symptoms, as well as anti-psychotics and mood stabilisers, like lithium. Psychological therapy, like cognitive behavioural therapy (CBT), may help patients manage how they think and act. In rare cases, electroconvulsive therapy can help with severe depression or mania. Most women with PP make a full recovery if treated correctly. Severe symptoms tend to last between two and 12 weeks. However, it can take a year or more for women to recover. A PP episode can be followed by a period of depression, anxiety and low confidence. Some women then struggle to bond with their baby or feel like they missed out. These feelings can usually be overcome with the help of a mental health support team. Around half of women who have PP suffer again in future pregnancies. Those who are at high risk should receive specialist care from a psychiatrist while they are expecting. Source: NHS 'There was still a deep and enduring depression and so many anxieties.' They added: 'She put on a brave face, but she clearly missed having regular contacts that she had built up a good relationship with.' Having been discharged from the services, Ms Harron had to use local pharmacies to access her medication—many of which had issues with supply and distribution. Her family told the inquest that this caused her a lot of anxiety and played a role in the tragic spiral that lead to her death. In response, Dr Aneesa Peer, a consultant psychiatrist based at the South London and Maudsley trust said when Ms Harron was discharged she was in remission. 'When patients are dealing well and are stable for at least a year and they are on a good treatment regime they are considered for discharge,' she said. Following this period, they can return back to the specialist services under a scheme that ensures they will be seen within four weeks, rather than being added to longer waiting lists. 'She didn't refer herself back after being discharged,' Dr Peer told the inquest. 'Roisin was very astute around her medication and would advocate for herself very clearly and concisely. 'This is not someone who is waiting on support,' Dr Peer told the court. 'Patients come back to us all the time. The door is open. I am not sure how we could have intervened.' Mr Harron, a retired social worker, also told the could he felt this attitude towards his daughter's treatment was 'too blase' and it was 'impossible to underestimate the impact' it had in his daughters life. Ms Harron was found dead at the London Crystal Palace Travelodge on June 17, 2024, just over a year after being discharged from specialist services. A postmortem examination revealed that she had overdosed and a number of prescription drugs were found in her system. Dr Mihir Khan, who carried out the examination, concluded she died of cardiac arrest triggered by an overdose. Assistant coroner Victoria Webb confirmed death by suicide, adding that Ms Haron had suffered with postpartum psychosis. Postpartum Psychosis affects roughly one in 1,000 women every year. It is different from the 'baby blues', which many mothers experience while they struggle to cope with the stress and hormonal changes that come with having children. It is also different from postnatal depression, which affects one in 10 women to some extent. This can cause feelings of helplessness, as well as a loss of interest in the baby and crying frequently. Postpartum Psychosis symptoms usually start within the first two weeks. Common signs include manic moods, feeling paranoid or afraid, acting out of character, confusion and restlessness. Little is known about exactly how or what triggers the illness and so far little evidence to suggest it can be linked to a traumatic birth. Antidepressants may be prescribed to ease symptoms, as well as anti-psychotics and mood stabilisers, like lithium, according to the NHS. Psychological therapy, like cognitive behavioural therapy (CBT), may help patients manage how they think and act. In rare cases, electroconvulsive therapy can help with severe depression or mania. Most women with PP make a full recovery if treated correctly. If you, or someone close to you, is experiencing postpartum psychosis, talk to a midwife, GP, health visitor or dial 111 - if there is an immediate threat to life, call 999. You can also call the Samaritans on 116123.
STV News
an hour ago
- STV News
Two NHS boards ordered to apologise for failings in cancer patient's care
Two NHS boards have been ordered to apologise for failings in the care of a patient who had two cancers at the same time and died. A watchdog investigated complaints raised by the patient's family against NHS Orkney and NHS Grampian. Identified as patient A, the person had been receiving treatment for bladder and bowel cancer. During the investigation, the Scottish Public Services Ombudsman (SPSO) took advice from a cancer surgeon on the services provided the patient. The watchdog concluded that NHS Grampian delayed in initiating treatment for the patient's bowel cancer, and that the reviews it carried out were 'inadequate'. It was also found that NHS Orkney failed to mark an MRI scan request as urgent. The SPSO said there was a failure to provide a reasonable standard of care and treatment to patient A, and that both authorities had failed to meet obligations on transparency around the patient's care. They ordered both health boards to apologise to the patient's family and made a number of recommendations for improvements. On NHS Grampian, the watchdog said: 'We found that there was a failure to provide a reasonable standard of care and treatment to A, particularly in relation to delays in initiating treatment for their colorectal (bowel) cancer.' The report said, regarding NHS Orkney, said: 'We found that there was a failure to provide a reasonable standard of care and treatment to A, particularly in relation to a failure to mark an MRI scan request as urgent and a failure to report the results of scopes in the normal way.' STV News has contacted the NHS boards for comment. Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
